| First Author | Dimitriadis GK | Year | 2019 |
| Journal | Mol Cell Endocrinol | Volume | 494 |
| Pages | 110487 | PubMed ID | 31195080 |
| Mgi Jnum | J:278661 | Mgi Id | MGI:6357650 |
| Doi | 10.1016/j.mce.2019.110487 | Citation | Dimitriadis GK, et al. (2019) Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. Mol Cell Endocrinol 494:110487 |
| abstractText | The effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of apolipoprotein E knockout [Apo-E ((-/-))] mice were evaluated in this study. Empagliflozin-treated mice had lower total cholesterol (P<0.05), fasting glucose (P<0.01), heart rate (P<0.01) and diastolic blood pressure (DBP) (P<0.05) compared to controls. Histomorphometry revealed reduced atherosclerotic lesion progress approaching statistical significance (P=0.06) and approximately 50% wider lumen area for the Empagliflozin treated mice group. Although empagliflozin significantly reduced Vcam-1 and Mcp-1 (P<0.05, P<0.01, respectively) and marginally induced Timp-1 and Timp-2 mRNA expression (P<0.08, P=0.1 respectively), immunohistochemistry revealed a marginal reduction in VCAM-1 and MMP-9 (P=0.1) without affecting the expression of TIMP-2 and MCP-1 in atherosclerotic lesions. Empagliflozin improves primary haemodynamic parameters and attenuates the progression of atherosclerosis by reducing hyperlipidemia and hyperglycemia, while direct actions in aorta vessel mediated via SGLT-1 are strongly hypothesized. |
